Compare GSIT & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GSIT | HUMA |
|---|---|---|
| Founded | 1995 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 196.4M | 165.7M |
| IPO Year | 2004 | 2020 |
| Metric | GSIT | HUMA |
|---|---|---|
| Price | $4.78 | $0.40 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $1.63 |
| AVG Volume (30 Days) | 427.7K | ★ 3.4M |
| Earning Date | 10-29-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 79.37 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $25,122,000.00 | $2,038,000.00 |
| Revenue This Year | N/A | $72.32 |
| Revenue Next Year | $12.85 | $518.79 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 22.44 | N/A |
| 52 Week Low | $4.51 | $0.44 |
| 52 Week High | $18.14 | $1.90 |
| Indicator | GSIT | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 33.72 | 22.39 |
| Support Level | $4.69 | N/A |
| Resistance Level | $5.86 | $0.75 |
| Average True Range (ATR) | 0.22 | 0.03 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 6.20 | 5.99 |
GSI Technology Inc is a provider of semiconductor memory solutions. The company develops and markets high-performance memory products, including Very Fast static random access memory, or SRAM, that are incorporated in high-performance networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations, and network access equipment. It sells these products to original equipment manufacturers and customers including Nokia and customers segregated as-Contract manufacturers, Distribution and OEMs. In addition, it serves the ongoing needs of the military, aerospace and medical markets for high-performance SRAMs. It operates geographically in China, Singapore, the Netherlands, Germany, Rest of the world, and USA.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.